Literature DB >> 22544614

Expression of transforming growth factor-β1 (TGF-β1) and E-cadherin in glioma.

Liu Yang1, Mei Liu, Chuanzong Deng, Zhikai Gu, Yilu Gao.   

Abstract

Gliomas are the most common tumors in the central nervous system. This study aims to investigate the expressions of transforming growth factor-β1 (TGF-β1) and epithelial cadherin (E-cadherin) in human brain glioma tissues and the correlation between their expressions with clinical pathological features and clinical significance. The expressions of mRNA or protein of TGF-β1 and E-cadherin were detected by using reverse transcription polymerase chain reaction (RT-PCR) and Western blot in these tissues. Positive rates of the expression of TGF-β1 and E-cadherin were 62.9 % and 38.6 % in brain tissues of glioma patients. The expressions of mRNA or protein for TGF-β1 in brain glioma tissues were significantly higher than that in normal brain tissues (p < 0.01). Their expressions in well-differentiated glioma brain tissues were lower than those in poorly differentiated glioma brain tissues (p < 0.01). A negative correlation was found between TGF-β1 and E-cadherin in brain glioma tissues (r = -0.302, p < 0.011). The cell numbers of C6 glioma through Transwell chambers were decreased significantly (p < 0.01), and the expression of TGF-β1 was downregulated significantly (p < 0.01). However, the expression of E-cadherin was upregulated significantly (p < 0.01) after transfecting TGF-β1 siRNA. The expression changes of TGF-β1 and E-cadherin may be related to the emergence and the development of glioma. Downregulation of TGF-β1 expression using siRNA can decrease the invasive capability of C6 glioma cells.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22544614     DOI: 10.1007/s13277-012-0398-z

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  39 in total

Review 1.  Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas.

Authors:  Marc C Chamberlain
Journal:  Expert Rev Neurother       Date:  2010-10       Impact factor: 4.618

Review 2.  Current view of the role of transforming growth factor beta 1 in skin carcinogenesis.

Authors:  Allen Guanqun Li; Shi-Long Lu; Gangwen Han; Molly Kulesz-Martin; Xiao-Jing Wang
Journal:  J Investig Dermatol Symp Proc       Date:  2005-11

3.  MicroRNAs and esophageal cancer.

Authors:  Santosh Kumar Patnaik; Reema Mallick; Sai Yendamuri
Journal:  J Gastrointest Oncol       Date:  2010-09

4.  Epithelial mesenchymal transition and lung cancer.

Authors:  Dakai Xiao; Jianxing He
Journal:  J Thorac Dis       Date:  2010-09       Impact factor: 2.895

Review 5.  The relationship between fibrogenic TGFβ1 signaling in the joint and cartilage degradation in post-injury osteoarthritis.

Authors:  A Plaas; J Velasco; D J Gorski; J Li; A Cole; K Christopherson; J D Sandy
Journal:  Osteoarthritis Cartilage       Date:  2011-05-17       Impact factor: 6.576

Review 6.  On the origin and growth of gliomas.

Authors:  Davide Schiffer; Laura Annovazzi; Valentina Caldera; Marta Mellai
Journal:  Anticancer Res       Date:  2010-06       Impact factor: 2.480

Review 7.  TGF-beta1-induced epithelial-to-mesenchymal transition and therapeutic intervention in diabetic nephropathy.

Authors:  Claire E Hills; Paul E Squires
Journal:  Am J Nephrol       Date:  2009-11-04       Impact factor: 3.754

Review 8.  Immunoregulatory pathways controlling progression of autoimmunity in NOD mice.

Authors:  Sylvaine You; Marie-Alexandra Alyanakian; Berta Segovia; Diane Damotte; Jeffrey Bluestone; Jean-François Bach; Lucienne Chatenoud
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

Review 9.  Growth Factors and their receptors in cancer metastases.

Authors:  Shi Yu Yang; Anur Miah; Amit Pabari; Marc Winslet
Journal:  Front Biosci (Landmark Ed)       Date:  2011-01-01

10.  Small RNA and its application in andrology and urology.

Authors:  Ji Wang; Long-Cheng Li
Journal:  Transl Androl Urol       Date:  2012
View more
  8 in total

1.  The Clinical Implications of Transforming Growth Factor Beta in Pathological Grade and Prognosis of Glioma Patients: A Meta-Analysis.

Authors:  Xiangshan Yang; Shunzeng Lv; Xingtong Zhou; Yuting Liu; Daotang Li; Ranran Shi; Huihui Kang; Jing Zhang; Zhongfa Xu
Journal:  Mol Neurobiol       Date:  2014-08-23       Impact factor: 5.590

2.  Riparsaponin isolated from Homonoia riparia Lour induces apoptosis of oral cancer cells.

Authors:  Tiecheng Li; Lei Wang
Journal:  Oncol Lett       Date:  2017-09-25       Impact factor: 2.967

3.  Knockdown of T Cell Immunoglobulin and Mucin 1 (Tim-1) Suppresses Glioma Progression Through Inhibition of the Cytokine-PI3K/AKT Pathway.

Authors:  Peng Zhou; Maoxing Fei; Yanling Han; Mengliang Zhou; Handong Wang
Journal:  Onco Targets Ther       Date:  2020-08-04       Impact factor: 4.147

4.  Overexpression of integrin-linked kinase (ILK) promotes glioma cell invasion and migration and down-regulates E-cadherin via the NF-κB pathway.

Authors:  Feng Liang; Shuqin Zhang; Bing Wang; Jianwu Qiu; Yunjie Wang
Journal:  J Mol Histol       Date:  2013-09-13       Impact factor: 2.611

5.  Regulation of Glioma Cells Migration by DYRK2.

Authors:  Yifen Shen; Li Zhang; Donglin Wang; Yifeng Bao; Chao Liu; Zhiwei Xu; Wei Huang; Chun Cheng
Journal:  Neurochem Res       Date:  2017-07-04       Impact factor: 3.996

6.  Differences in the Expression Patterns of TGFβ Isoforms and Associated Genes in Astrocytic Brain Tumors.

Authors:  Natalia Kurowska; Barbara Strzalka-Mrozik; Marcel Madej; Klaudia Pająk; Celina Kruszniewska-Rajs; Wojciech Kaspera; Joanna Magdalena Gola
Journal:  Cancers (Basel)       Date:  2022-04-08       Impact factor: 6.575

Review 7.  Transcription regulation of E-cadherin by zinc finger E-box binding homeobox proteins in solid tumors.

Authors:  Thian-Sze Wong; Wei Gao; Jimmy Yu-Wai Chan
Journal:  Biomed Res Int       Date:  2014-08-13       Impact factor: 3.411

8.  Candidate genes and microRNAs for glioma pathogenesis and prognosis based on gene expression profiles.

Authors:  Chen Xie; Meng Xu; Dejuan Lu; Weiguang Zhang; Laizang Wang; Hongwei Wang; Jianhua Li; Fubin Ren; Chao Wang
Journal:  Mol Med Rep       Date:  2018-06-29       Impact factor: 2.952

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.